22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021
(NYSE American: XXII ), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today reported results for the second quarter ended June 30, 2021, and provided an update on recent business highlights.
- (NYSE American: XXII ), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today reported results for the second quarter ended June 30, 2021, and provided an update on recent business highlights.
- Total operating expenses for the second quarter of 2021 increased by $2.3 million compared to the prior year period.
- Operating loss for the second quarter of 2021 was $(6.6) million, an increase of $1.9 million compared to the prior year period.
- 22nd Century will host a live webcast today at 10:00 a.m.ET to discuss its second quarter 2021 financial results and business highlights.